A volatile biomarker in breath predicts lung cancer and pulmonary nodules

被引:39
|
作者
Phillips, Michael [1 ,2 ]
Bauer, Thomas L. [3 ,4 ]
Pass, Harvey, I [5 ]
机构
[1] Menssana Res Inc, 1 Horizon Rd,Suite 1415, Ft Lee, NJ 07024 USA
[2] New York Med Coll, Dept Med, Valhalla, NY 10595 USA
[3] Christiana Care Hlth Syst, Newark, DE USA
[4] 19 Davis Ave, Neptune City, NJ 07753 USA
[5] NYU, Langone Med Ctr, 550 1St Ave, New York, NY USA
关键词
breath; volatile organic compounds; biomarker; pulmonary nodules; CORONARY-ANGIOGRAPHY; ORGANIC-COMPOUNDS; OXIDATIVE STRESS; PROBABILITY; PRETEST; AIR;
D O I
10.1088/1752-7163/ab21aa
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Background: previous studies have reported volatile organic compounds (VOCs) in the breath as apparent biomarkers of lung cancer. We tested the hypothesis that a robust breath VOC biomarker of lung cancer should also predict pulmonary nodules in chest CT images. Methods: Biomarker discovery study (unblinded): 301 subjects were screened for lung cancer with low dose chest CT (LDCT), and donated duplicate samples of alveolar breath for analysis with gas chromatography mass spectrometry (GC MS). Monte Carlo analysis of breath chromatograms revealed a mass ion as a biomarker that identified biopsy-proven lung cancer as well as suspicious pulmonary nodules on LDCT. The biomarker was termed Mass Abnormalities in Gaseous Ions with Imaging Correlates (MAGIIC). The chemical structure of MAGIIC was tentatively identified from the NIST library of mass spectra; the best-fit compounds included C4 and C5 alkane derivatives that were consistent with metabolic products of oxidative stress. Blinded validation of MAGIIC: the abundance of the MAGIIC biomarker was determined in a different group of 161 subjects undergoing screening with LDCT. They donated duplicate alveolar breath VOC samples that were analyzed at two independent laboratories. The study was blinded and monitored with Good Clinical Practice. The abundance of MAGIIC in breath predicted biopsy-proven lung cancer with 84% accuracy, sensitivity = 75.4% and specificity = 85.0%. MAGIIC also predicted pulmonary nodules in LDCT with 80.5% accuracy, sensitivity = 80.1% and specificity = 75.0%. Breath MAGIIC abundance was not significantly affected by tobacco smoking history. Conclusions: in a blinded study, breath VOC MAGIIC accurately predicted lung cancer confirmed on a tissue biopsy, as well as suspicious pulmonary nodules observed on LDCT. MAGIIC may have been a product of oxidative stress and it could potentially be employed as an ancillary to LDCT to predict the likelihood that a pulmonary nodule is malignant.
引用
收藏
页数:6
相关论文
共 50 条
  • [1] Comment on 'volatile biomarker in breath predicts lung cancer and pulmonary nodules'
    Modak, A. S.
    Ruzsanyi, V.
    Mochalski, P.
    Mayhew, C. A.
    JOURNAL OF BREATH RESEARCH, 2020, 14 (02)
  • [2] Reply to Comment on 'Volatile biomarker in breath predicts lung cancer and pulmonary nodules'
    Phillips, Michael
    Bauer, Thomas L.
    Pass, Harvey I.
    JOURNAL OF BREATH RESEARCH, 2020, 14 (02)
  • [3] A Volatile Biomarker in Breath Predicts Pulmonary Nodules in Chest CT images
    Phillips, M.
    Bauer, T. L.
    Pass, H. I.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [4] The Analysis of Volatile Organic Compound Profiles in the Breath as a Biomarker of Lung Cancer
    Mazzone, Peter
    Wang, Xiaofeng
    Rhodes, Paul
    Martino, Ray
    Lim, Sung
    Beukeman, Mary
    Seeley, Meredith
    Choi, Humberto
    Jett, James
    CHEST, 2013, 144 (04)
  • [5] Exhaled breath volatile biomarker analysis for thyroid cancer
    Guo, Lei
    Wang, Changsong
    Chi, Chunjie
    Wang, Xiaoyang
    Liu, Shanshan
    Zhao, Wei
    Ke, Chaofu
    Xu, Guowang
    Li, Enyou
    TRANSLATIONAL RESEARCH, 2015, 166 (02) : 188 - 195
  • [6] Detection of lung cancer with volatile markers in the breath
    Phillips, M
    Cataneo, RN
    Cummin, ARC
    Gagliardi, AJ
    Gleeson, K
    Greenberg, J
    Maxfield, RA
    Rom, WN
    CHEST, 2003, 123 (06) : 2115 - 2123
  • [7] Radiomics of pulmonary nodules and lung cancer
    Wilson, Ryan
    Devaraj, Anand
    TRANSLATIONAL LUNG CANCER RESEARCH, 2017, 6 (01) : 86 - 91
  • [8] Protein biomarker panel distinguishes malignant lung cancer lesions from benign pulmonary nodules
    Birse, Charles E.
    FitzHugh, William M.
    Heidbrink, Jenny
    Dhariwal, Gulshan
    Pollard, Thomas
    Doiron, Luke
    Schreeder, Marshall
    Ruben, Steve M.
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (06) : S228 - S229
  • [9] Circulating Genetically Abnormal Cells Predicts Risk of Lung Cancer in Individuals with Indeterminant Pulmonary Nodules
    Katchman, B. A.
    Tahvilian, S.
    Kuban, J. D.
    Yankelevitz, D. F.
    Leventon, D.
    Henschke, C. I.
    Zhu, J.
    Baden, L.
    Yip, R.
    Hirsch, F. R.
    Reed, R.
    Brown, A.
    Muldoon, A.
    Trejo, M.
    Donovan, M. J.
    Pagano, P. C.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (03) : E13 - E13
  • [10] Volatile compounds of exhaled breath in lung cancer and lung inflammatory disease
    Kislina, Agnese
    Balode, Liga
    Bukovskis, Mans
    Strazda, Gunta
    Jurka, Normunds
    Kopeika, Uldis
    Logina, Liene
    Taivans, Lmmanuels
    EUROPEAN RESPIRATORY JOURNAL, 2013, 42